187 related articles for article (PubMed ID: 32616859)
1. Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.
van der Vos KE; Vis DJ; Nevedomskaya E; Kim Y; Choi W; McConkey D; Wessels LFA; van Rhijn BWG; Zwart W; van der Heijden MS
Sci Rep; 2020 Jul; 10(1):10952. PubMed ID: 32616859
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
[TBL] [Abstract][Full Text] [Related]
3. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer.
Wu S; Nitschke K; Worst TS; Fierek A; Weis CA; Eckstein M; Porubsky S; Kriegmair M; Erben P
J Exp Clin Cancer Res; 2020 Dec; 39(1):288. PubMed ID: 33334367
[TBL] [Abstract][Full Text] [Related]
6. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
7. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.
Xu Z; Yu YQ; Ge YZ; Zhu JG; Zhu M; Zhao YC; Xu LW; Yang XB; Geng LG; Dou QL; Jia RP
Tumour Biol; 2015 Sep; 36(10):8159-66. PubMed ID: 25990459
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
[TBL] [Abstract][Full Text] [Related]
10. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
11. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
Seiler R; Gibb EA; Wang NQ; Oo HZ; Lam HM; van Kessel KE; Voskuilen CS; Winters B; Erho N; Takhar MM; Douglas J; Vakar-Lopez F; Crabb SJ; van Rhijn BWG; Fransen van de Putte EE; Zwarthoff EC; Thalmann GN; Davicioni E; Boormans JL; Dall'Era M; van der Heijden MS; Wright JL; Black PC
Clin Cancer Res; 2019 Aug; 25(16):5082-5093. PubMed ID: 30224344
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
[TBL] [Abstract][Full Text] [Related]
13. Increased CD4
Ahlén Bergman E; Hartana CA; Johansson M; Linton LB; Berglund S; Hyllienmark M; Lundgren C; Holmström B; Palmqvist K; Hansson J; Alamdari F; Huge Y; Aljabery F; Riklund K; Winerdal ME; Krantz D; Zirakzadeh AA; Marits P; Sjöholm LK; Sherif A; Winqvist O
Clin Epigenetics; 2018 Aug; 10(1):102. PubMed ID: 30075815
[TBL] [Abstract][Full Text] [Related]
14. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
[TBL] [Abstract][Full Text] [Related]
15. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
16. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
18. Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes.
Ruan JL; Hsu JW; Browning RJ; Stride E; Yildiz YO; Vojnovic B; Kiltie AE
Eur Urol Oncol; 2019 May; 2(3):239-247. PubMed ID: 31200837
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
20. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
Xue Y; Tong L; LiuAnwei Liu F; Liu A; Zeng S; Xiong Q; Yang Z; He X; Sun Y; Xu C
Oncol Rep; 2019 Aug; 42(2):581-594. PubMed ID: 31233191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
